On that—and, Bruce, I'd like you to comment as well—it seems to me that things haven't changed to any great extent in terms of government being able to ward off big pressures from drug companies to push something on the market without the tests being done and without the precautionary principle being followed.
I'd like to go back to Gardasil, because the first that I know this issue came up in terms of the public and Parliament was when Merck Frosst appeared before the finance committee in Montreal, before the 2006 federal budget, pushing this vaccine. We hadn't heard about it before. We hadn't heard that this was an answer to a serious problem. And suddenly in the budget, without any further studies or talk, there appeared $300 million for a vaccine that may not have been fully tested or may not be fully cost-effective. So I'm wondering what we do to prevent this kind of situation from repeatedly happening, where drugs get on the market, treatments get on the market, and in effect often women are the guinea pigs, or maybe children.